Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform

Posted : Wed, 04 Nov 2009 15:01:54 GMT
Author : Neuronascent, Inc.
Category : Press Release
News Alerts by Email ( click here )
News | Home
CLARKSVILLE, Md., Nov. 4 MD-Neuronascent-ChemR

CLARKSVILLE, Md., Nov. 4 /PRNewswire/ -- Neuronascent, Inc., a privately-held biotechnology company developing novel, neurogenic small-molecule drugs for the treatment of depression, Alzheimer's disease, Parkinson's and other neurodegenerative diseases, announces it has entered into a discovery agreement with ChemRar Pharma, a Russian biotechnology start-up company focusing on small-molecule modulators for developmental pathways and stem cells to treat cancer. Under the terms of the agreement, Neuronascent will screen certain ChemRar proprietary developmental pathway inhibitors utilizing their proprietary drug discovery platform for neurogenesis and neuroprotection. Financial terms of the collaboration were not disclosed.

The agreement matches ChemRar's discovery and translational research focus through scientific collaboration with Neuronascent's success in discovering novel, neurogenic and neuroprotective drug candidates. The companies intend to evaluate co-development opportunities for future commercialization and funding.

"We are proud to start this collaboration with ChemRar Pharma on these studies, highlighting our expertise in the field of neurogenesis, and look forward to the potential of this relationship," notes Dr. Judith Kelleher-Andersson, President and CSO, Neuronascent, Inc.

Nikolay Merkin, CBO of ChemRar Pharma, comments: "We are pleased that Neuronascent will bring high value to our R&D program and expand the scope of our molecules with their unique and well-established stem cell and neurogenesis platform. We look forward to achieving success in this collaboration."

About ChemRar Pharma:
ChemRar Pharma was established in 2007 in Moscow, Russia under the roof of the ChemRar High Tech Center as an innovative oncology start-up. In 2009, ChemRar in-licensed the portfolio of developmental pathway inhibitors from AllaChem and ChemDiv, Inc. (San Diego, CA) and established the R&D collaboration with ChemDiv's Chemical Diversity Research Institute in Moscow to continue preclinical and clinical development for multiple cancer indications.

About Neuronascent, Inc.:
Founded in 2004 by Dr. Judith Kelleher-Andersson, Neuronascent, Inc. discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression, neurodegenerative diseases, including Alzheimer's and Parkinson's, and Down syndrome. The Company is headquartered in Clarksville, MD and has facilities in Rockville and Walkersville, MD. For additional information, please visit www.neuronascent.com.

Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects" and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ moderately from current expectations.

SOURCE Neuronascent, Inc.


Copyright © 2008 PR Newswire. All rights reserved.

Share/Save/Bookmark

Article : Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform
Print this article
Share this article

Stay Updated

News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Related News

Reportlinker Adds Routers - A Global Update of Market Trends & Opportunities
NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Research and Markets: This Essential Report Analyzes Enterprise Portals
DUBLIN - Research and Markets (

Reportlinker Adds Pain Management - Global Trends
NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Reportlinker Adds Fire Suppression Systems - A North American and European Market Analysis
NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antisoma to present at Piper Jaffray Health Care Conference
LONDON -- 11/25/09 -- 25 November 2009, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Chief Executive Officer, Glyn Edwards, will present an overview of the Company's strategy, programmes and prospects at ..

Reportlinker Adds Key Players in the Global Confectionery Industry (5th Edition)
NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Research and Markets: This Essential Report Analyzes the Market for Electronic Invoice Presentment & Payment
DUBLIN - Research and Markets (

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.